Status
Conditions
Treatments
About
To determine the detection rate of driver oncogenes and resistance mechanisms in cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS) progression) and concordance with plasma/tissue
Full description
To determine the detection rate of driver oncogenes and resistance mechanisms in cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS) progression) and concordance with plasma/tissue
Sex
Ages
Volunteers
Inclusion criteria
Provision to sign and date the consent form
Stated willingness to comply with all study procedures and be available for the duration of the study.
Be aged 18 or older.
Pathologically confirmed NSCLC with EGFR-mutation, or ALK- or ROS1-rearrangement and currently on an EGFR, or ALK or ROS1 tyrosine-kinase inhibitor (TKI) as applicable
Stage IV NSCLC disease according to AJCC 8th edition
Known CNS metastasis prior to current line of therapy with CR/PR/SD for at least 6 months (not purely attributable to prior local therapy such as radiation) on current EGFR, or ALK or ROS1 TKI, confirmed by at least one of the following modalities:
Confirmed current CNS progression, with or without eCNS progression, on the same TKI based on at least one of the following modalities:
Prior CNS radiation therapy is allowed
Exclusion criteria
Has contraindications to receive a lumbar puncture which may include, but are not limited to the following, at the discretion of the patient's oncologist or physician performing the LP:
History of a second primary malignancy (including a second primary lung cancer) with the exceptions for:
Women who are documented as pregnant or breastfeeding
0 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal